AstraZeneca Business Objects Case StudyDocument Transcript
B I S TA NDA R D IZ AT I O N
1 To improve
visibility and access
of global R&D
information to over “In this highly competitive business sector, time-to-market dictates brand leadership
5,000 R&D users
globally and revenue generation. Business Objects business intelligence solution has enabled
AstraZeneca to improve project management, cost control, and resource utilization,
Dashboard and is helping us achieve competitive research and development timescales.”
Manager will David Scanlon, Business Manager, AstraZeneca
indicators to senior
Critical Need to Reduce “To support our requirement to accelerate drug
development, AstraZeneca requires fast and easy
access to global R&D information,” says Chris
1 Global AstraZeneca has over 12,000 research and Saxby, IT Consultant, AstraZeneca.
transparency of development (R&D) employees across six
international sites and spends over $3 billion Improved Visibility to R&D Data
1 Improved resource
annually on R&D, the equivalent of over $10
utilization To provide complete visibility of R&D
million every working day.
1 Tighter cost control information across the world, AstraZeneca
1 Accelerating drug Drug development is highly competitive, and has developed and deployed the Matrix
each day they saved getting a new brand to project management system. This system uses
market saves millions of dollars. Drug patents BusinessObjects to query and analyze global
last 20-25 years, and it typically takes 8-12 R&D information stored centrally in an Oracle
years to bring a drug to market. Therefore, the data warehouse.
shorter the product development and clinical
Over 5,000 users across AstraZeneca's six
trial, the longer a company has to establish
international R&D sites can access and
brand leadership and generate revenues
interrogate information on project schedules,
before a competitor can bring generic
project costs, and resource utilization.
products to market.
In addition, the company has selected
Reduced time-to-market is dependent upon BusinessObjects as its standard business
maximizing project management efficiency, intelligence solution, and it is used across
resource utilization, and cost control. other core areas of the business such as
Immediate access to one consistent view of manufacturing, finance, and marketing.
R&D information is critical to support these
P H A R M AC E U T I CA L / H E A LT H CA R E 99
“ Immediate access to R&D information is a critical
component in the race to be first-to-market in the
pharmaceutical industry. With BusinessObjects,
we now have a platform to deliver this
information globally in a flexible manner that
supports constant innovation and change.
As a result, we aim to speed development, better
manage costs, and ultimately reduce time-to-
market. Productivity is the key industry challenge.
The pharmaceutical giant is also implementing This fast and easy access to R&D data provides a
BusinessObjects Dashboard Manager in conjunction greater global view of project activity and of how
with Advizor Solutions technology to deliver much R&D is spending on developing new
dynamic at-a-glance displays that show the status products. And this R&D insight enables more
of key performance indicators across R&D to senior accurate project scheduling, project budgeting,
management. and resource allocation—helping AstraZeneca to
plan more effectively and reduce costs.
According to Saxby, “Business Objects solutions are
transforming the availability and accessibility of R&D Leveraging the information provided by
project information within AstraZeneca.” BusinessObjects, AstraZeneca is gaining a
significant competitive edge by accelerating its
BI Enables Competitive Edge time-to-market for new products. A faster
development process helps AstraZeneca to launch
BI solutions from Business Objects enable
products earlier in order to secure early brand
AstraZeneca to track, understand, and manage the
leadership and increased revenues.
huge volumes of project data that it creates every
day. Senior management, development teams, and
therapeutic area teams all have instant access to
one consolidated view of up-to-date R&D
information to help them make faster and more
AstraZeneca is one of the world’s leading pharmaceutical companies, engaged in the
1 Sales figures:
$18.849 million research, development, manufacture, and marketing of prescription pharmaceuticals and
1 Staff: the supply of healthcare services. AstraZeneca has sales activities in over 100 countries
12,000 in R&D
and manufacturing facilities in 19 countries.
1 Date founded: